<DOC>
	<DOCNO>NCT00378066</DOCNO>
	<brief_summary>The purpose study determine efficacy safety bevacizumab/capecitabine/oxaliplatin combination metastatic recurrent Korean colorectal cancer .</brief_summary>
	<brief_title>Phase II Study Bevacizumab , Capecitabine Oxaliplatin Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically document colorectal adenocarcinoma ECOG performance status 2 low Adequate bone marrow function Adequate kidney function Adequate liver function Informed consent Major surgical procedure significant traumatic injury within 28 day prior study treatment start Known allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>